CN101456910B - 林蛙抗菌肽及制备工艺和在抗病毒药物中的应用 - Google Patents
林蛙抗菌肽及制备工艺和在抗病毒药物中的应用 Download PDFInfo
- Publication number
- CN101456910B CN101456910B CN2008100514230A CN200810051423A CN101456910B CN 101456910 B CN101456910 B CN 101456910B CN 2008100514230 A CN2008100514230 A CN 2008100514230A CN 200810051423 A CN200810051423 A CN 200810051423A CN 101456910 B CN101456910 B CN 101456910B
- Authority
- CN
- China
- Prior art keywords
- wood frog
- antibiotic peptides
- antiviral
- supernatant
- peptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 59
- 241000191896 Rana sylvatica Species 0.000 title claims abstract description 56
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 50
- 230000003115 biocidal effect Effects 0.000 title claims abstract description 45
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 238000005516 engineering process Methods 0.000 title description 4
- 239000003443 antiviral agent Substances 0.000 title 1
- 229920001184 polypeptide Polymers 0.000 claims abstract description 10
- 239000006228 supernatant Substances 0.000 claims description 15
- 239000003910 polypeptide antibiotic agent Substances 0.000 claims description 14
- 239000008351 acetate buffer Substances 0.000 claims description 5
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 5
- 230000008021 deposition Effects 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 239000000243 solution Substances 0.000 claims description 5
- 239000007788 liquid Substances 0.000 claims description 3
- 238000002791 soaking Methods 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 22
- 229940024606 amino acid Drugs 0.000 abstract description 16
- 235000001014 amino acid Nutrition 0.000 abstract description 16
- 150000001413 amino acids Chemical class 0.000 abstract description 16
- 229940079593 drug Drugs 0.000 abstract description 14
- 230000000840 anti-viral effect Effects 0.000 abstract description 12
- 230000000694 effects Effects 0.000 abstract description 11
- 208000002672 hepatitis B Diseases 0.000 abstract description 9
- 206010022000 influenza Diseases 0.000 abstract description 9
- 208000030507 AIDS Diseases 0.000 abstract description 7
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 abstract description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 abstract description 3
- 230000002378 acidificating effect Effects 0.000 abstract description 3
- 229930182817 methionine Natural products 0.000 abstract description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 abstract description 2
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 abstract description 2
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 abstract description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 abstract description 2
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 abstract description 2
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 abstract description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004473 Threonine Substances 0.000 abstract description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Chemical compound CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 abstract description 2
- 230000002949 hemolytic effect Effects 0.000 abstract description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract description 2
- 239000004475 Arginine Substances 0.000 abstract 1
- CKLJMWTZIZZHCS-UHFFFAOYSA-N D-OH-Asp Natural products OC(=O)C(N)CC(O)=O CKLJMWTZIZZHCS-UHFFFAOYSA-N 0.000 abstract 1
- CKLJMWTZIZZHCS-UWTATZPHSA-N D-aspartic acid Chemical compound OC(=O)[C@H](N)CC(O)=O CKLJMWTZIZZHCS-UWTATZPHSA-N 0.000 abstract 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 abstract 1
- 239000004471 Glycine Substances 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 abstract 1
- 235000004279 alanine Nutrition 0.000 abstract 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 abstract 1
- 229960005261 aspartic acid Drugs 0.000 abstract 1
- 230000015271 coagulation Effects 0.000 abstract 1
- 238000005345 coagulation Methods 0.000 abstract 1
- 235000013922 glutamic acid Nutrition 0.000 abstract 1
- 239000004220 glutamic acid Substances 0.000 abstract 1
- 241000700605 Viruses Species 0.000 description 15
- 238000010790 dilution Methods 0.000 description 12
- 239000012895 dilution Substances 0.000 description 12
- 238000002474 experimental method Methods 0.000 description 10
- 241000700721 Hepatitis B virus Species 0.000 description 9
- 241000712461 unidentified influenza virus Species 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 7
- 102000004877 Insulin Human genes 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 231100001274 therapeutic index Toxicity 0.000 description 6
- 230000000007 visual effect Effects 0.000 description 6
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 101710162629 Trypsin inhibitor Proteins 0.000 description 3
- 229940122618 Trypsin inhibitor Drugs 0.000 description 3
- 238000005903 acid hydrolysis reaction Methods 0.000 description 3
- 230000002155 anti-virotic effect Effects 0.000 description 3
- 238000005227 gel permeation chromatography Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000002753 trypsin inhibitor Substances 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- 241000270959 Pelophylax nigromaculatus Species 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000000845 anti-microbial effect Effects 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 241000340668 Bombina maxima Species 0.000 description 1
- 241001415440 Bufo gargarizans Species 0.000 description 1
- 241000269420 Bufonidae Species 0.000 description 1
- 206010053567 Coagulopathies Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- XUYPXLNMDZIRQH-LURJTMIESA-N N-acetyl-L-methionine Chemical compound CSCC[C@@H](C(O)=O)NC(C)=O XUYPXLNMDZIRQH-LURJTMIESA-N 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- 239000006035 Tryptophane Substances 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 230000035602 clotting Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000013905 glycine and its sodium salt Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- 238000011005 laboratory method Methods 0.000 description 1
- 229960003136 leucine Drugs 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 229960005190 phenylalanine Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 229960004799 tryptophan Drugs 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 239000011800 void material Substances 0.000 description 1
Images
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
IC50(vg/ml) | EC50(vg/ml) | SI | |
林蛙抗菌肽 | 12.5 | 1.6 | 7.8 |
IC50(vg/ml) | EC50(vg/ml) | SI | |
林蛙抗菌肽 | 11.7 | 1.8 | 6.5 |
IC50(vg/ml) | EC50(vg/ml) | SI | |
林蛙抗菌肽 | 12.0 | 1.9 | 6.3 |
IC50(vg/ml) | EC50(vg/ml) | SI | |
林蛙抗菌肽 | 11.9 | 1.6 | 7.4 |
IC50(vg/ml) | EC50(vg/ml) | SI | |
林蛙抗菌肽 | 11.4 | 1.9 | 6.0 |
IC50(vg/ml) | EC50(vg/ml) | SI | |
林蛙抗菌肽 | 12.1 | 1.7 | 7.1 |
Claims (2)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100514230A CN101456910B (zh) | 2008-11-14 | 2008-11-14 | 林蛙抗菌肽及制备工艺和在抗病毒药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2008100514230A CN101456910B (zh) | 2008-11-14 | 2008-11-14 | 林蛙抗菌肽及制备工艺和在抗病毒药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN101456910A CN101456910A (zh) | 2009-06-17 |
CN101456910B true CN101456910B (zh) | 2012-07-25 |
Family
ID=40768056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN2008100514230A Active CN101456910B (zh) | 2008-11-14 | 2008-11-14 | 林蛙抗菌肽及制备工艺和在抗病毒药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN101456910B (zh) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101856323B (zh) * | 2010-06-11 | 2011-11-09 | 吉林大学 | 一种含林蛙抗菌肽的β-CD包合物栓剂及其制备方法 |
CN102250216B (zh) * | 2011-06-27 | 2013-03-06 | 昆明理工大学 | 黑斑蛙抗微生物肽及其基因和应用 |
CN103073628B (zh) * | 2013-02-01 | 2014-03-05 | 通化康元生物科技有限公司 | 一种利用超声波从林蛙体中提取抗菌肽的制备方法 |
CN103788192B (zh) * | 2014-01-24 | 2015-09-09 | 潍坊医学院 | 中华大蟾蜍抗菌肽bg-cath6(29)及其编码基因和应用 |
CN103755797B (zh) * | 2014-01-24 | 2015-07-01 | 潍坊医学院 | 中华大蟾蜍抗菌肽bg-cath6(5-29)及其编码基因和应用 |
CN103788180B (zh) * | 2014-01-24 | 2015-08-12 | 潍坊医学院 | 中华大蟾蜍抗菌肽bg-lw18及其编码基因和应用 |
CN110183528B (zh) * | 2019-06-05 | 2020-06-16 | 广州市涵美化妆品有限公司 | 抗菌肽及其用于制药和美容的用途 |
CN111944059B (zh) * | 2020-07-28 | 2022-03-01 | 中国农业大学 | 一种兼具抗菌、免疫调节、抗感染和抗炎活性的多功能杂合肽及其制备方法和应用 |
CN112704072B (zh) * | 2020-12-26 | 2021-09-14 | 通化康元生物科技有限公司 | 林蛙抗菌肽在制备抗新型冠状病毒SARS-CoV-2药物中的应用 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1216768A (zh) * | 1998-10-29 | 1999-05-19 | 吉林大学 | 生物抗菌肽及其制备方法 |
CN101041686A (zh) * | 2006-06-19 | 2007-09-26 | 辽宁师范大学 | 林蛙抗癌肽及其制备方法 |
-
2008
- 2008-11-14 CN CN2008100514230A patent/CN101456910B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1216768A (zh) * | 1998-10-29 | 1999-05-19 | 吉林大学 | 生物抗菌肽及其制备方法 |
CN101041686A (zh) * | 2006-06-19 | 2007-09-26 | 辽宁师范大学 | 林蛙抗癌肽及其制备方法 |
Non-Patent Citations (3)
Title |
---|
于文会,姜晓文.中国林蛙皮肤抗菌肽的分离纯化及部分特性研究.《黑龙江畜牧兽医》.2002,(第5期),3-4. * |
刘红玉,崔洪斌.中国林蛙(Rana chensinensis) 蛙皮抗菌肽的制备及抗菌作用研究.《中国食品卫生杂志》.2007,第19卷(第3期),217-221. * |
邱芳萍,周杰.从吉林林蛙干皮中提取抗菌肽.《吉林工学院学报》.2002,第23卷(第2期),4-6. * |
Also Published As
Publication number | Publication date |
---|---|
CN101456910A (zh) | 2009-06-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101456910B (zh) | 林蛙抗菌肽及制备工艺和在抗病毒药物中的应用 | |
CN103937864B (zh) | 一种从鳀鱼中分离的活性多肽 | |
CN109320588B (zh) | 一种刺参来源的ace抑制活性肽 | |
CN102164946B (zh) | 血管紧张素转换酶抑制肽 | |
CN101914149B (zh) | 一种具有抑菌活性的抗脂多糖因子的制备及应用 | |
CN115028704B (zh) | 一种抗酶解抗菌肽n1及其制备方法和应用 | |
CN108276485A (zh) | 能抑制和杀灭革兰氏阴性菌的抗菌肽hv2及制备方法 | |
CN109929897A (zh) | 一种促进hau-m1光合细菌菌群产氢的培养基及其应用 | |
CN108893515A (zh) | 高f值寡肽及其制备方法 | |
CN107252475B (zh) | 天然宿主防御肽Alligatorin4的应用 | |
CN110373346B (zh) | 枯草芽孢杆菌Bacillus sp.A-5及其用途 | |
CN104650208A (zh) | 一种鸡源抗菌肽的衍生肽及其制备方法和应用 | |
CN102391362B (zh) | 一组动物源性阳离子抗菌肽及其应用 | |
CN104593462A (zh) | 一种蓝蛤蛋白源ace抑制肽的制备方法 | |
CN103103196A (zh) | 一种修饰的山羊防御素基因及制备方法和应用 | |
CN106084140A (zh) | 一种含胍基基团的聚酰胺、其制备方法以及由其制得的水凝胶 | |
CN104892730B (zh) | 一种带鱼肝脏抗菌肽 | |
CN102199648A (zh) | 两种酶依次水解鹿血蛋白获取活性肽的方法 | |
CN113481270B (zh) | 一种从扇贝裙边中提取糖肽的方法 | |
CN1884574A (zh) | 血管紧张素转换酶抑制活性肽的生产方法 | |
CN1800208A (zh) | 一种蛇毒多肽及其制备方法 | |
CN111499691B (zh) | Ace抑制肽p1、其应用及其制备方法 | |
CN102002508A (zh) | 一种阿魏酸酯酶及其编码基因与应用 | |
CN102102117A (zh) | 适用降血压肽工程菌的培养基 | |
CN108117589B (zh) | 一种低值鱼抗氧化肽的分离纯化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210804 Address after: 130000 No. 2266, Jingkai Ring Road, Tonghua Development Zone, Tonghua City, Jilin Province Patentee after: TONGHUA KANG YUAN BIOLOGICAL TECHNOLOGY Co.,Ltd. Address before: 130012 No. 2699 Qianjin Street, Jilin, Changchun Patentee before: Jilin University |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Forest frog antibacterial peptide and its preparation process and application in antiviral drugs Effective date of registration: 20230324 Granted publication date: 20120725 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: TONGHUA KANG YUAN BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2023220000019 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Granted publication date: 20120725 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: TONGHUA KANG YUAN BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2023220000019 |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Forest frog antimicrobial peptide and its preparation process and application in antiviral drugs Granted publication date: 20120725 Pledgee: Tonghua Branch of China Everbright Bank Co.,Ltd. Pledgor: TONGHUA KANG YUAN BIOLOGICAL TECHNOLOGY Co.,Ltd. Registration number: Y2024220000023 |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right |